Circulating miRNAs in extracellular vesicles related to treatment response in patients with idiopathic membranous nephropathy

In O. Sun†, Yun‑Ui Bae†, Haekyung Lee3, Hyyoungae Kim3, Jin Seok Jeon3, Hyunjin Noh3, Jong‑Soo Choi4, Kyung‑Oh Doh4*† and Soon Hyo Kwon3*†

Abstract

Background: Extracellular vesicle (EV)‑microRNAs (miRNAs) are potential biomarkers for various renal diseases. This study attempted to identify the circulating EV‑miRNA signature not only for discriminating idiopathic membranous nephropathy (IMN) from idiopathic nephrotic syndrome (INS), but also to predict the treatment response of patients with IMN.

Methods: We prospectively enrolled 60 participants, including those with IMN (n = 19) and INS (n = 21) and healthy volunteers (HVs; n = 20) in this study. Using RNA sequencing, we assessed the serum EV‑miRNA profiles of all participants. To identify the EV‑miRNAs predictive of treatment response in IMN, we also analyzed EV‑miRNAs among patients with IMN with and without clinical remission.

Results: The expression levels of 3 miRNAs differed between IMN patients, INS patients and HVs. In addition, compared to HVs, RNA sequencing revealed differential expression of 77 and 44 EV‑miRNAs in patients with IMN without and with remission, respectively. We also identified statistically significant (|fold change ≥ 2, p < 0.05) differences in the expression levels of 23 miRNAs in IMN without remission. Biological pathway analysis of miRNAs in IMN without remission indicated that they are likely involved in various pathways, including renal fibrosis.

Conclusion: Our study identified EV‑miRNAs associated with IMN as well as those associations with therapeutic response. Therefore, these circulating EV‑miRNAs may be used as potential markers for the diagnosis and prediction of treatment response in patients with IMN.

Keywords: Extracellular vesicles, microRNAs, Glomerulonephritis, Treatment outcome

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
is the gold standard for differentiating glomerulonephritis from nephritic syndrome, it is an invasive procedure and can sometimes be dangerous in patients taking antiplatelet agents or anticoagulation medications. Therefore, in cases where there is a relative contraindication to renal biopsy, a serology-based approach to diagnosing IMN has been suggested in a previous study [6]. Studies have shown that the serum anti-phospholipase A2 receptor (PLA2R) antibody can be a potential biomarker for diagnosing, measuring disease activity, and predicting response to treatment in IMN [7–9]. Lower anti-PLA2R titers are associated with high rates of spontaneous remission in IMN, thus favoring conservative therapy, while declining anti-PLA2R titer levels after treatment predict clinical response to rituximab treatment [7]. However, the sensitivity of anti-PLA2R titer for the detection of IMN is low (between 52 and 78%) [10–13], and 20–30% of patients test negative for serum anti-PLA2R antibodies [14–16].

Extracellular vesicles (EVs) contain various molecules, including proteins, lipids, DNA, mRNA, and microRNA (miRNA), originating from the cell, and among these molecules, miRNAs have attracted the most attention since they can stably exist in various body fluids and play regulatory roles in gene expression [17, 18]. EV-miRNAs appear to be more stable than free miRNAs, as EVs seem to protect and increase the stability of miRNAs [19]. Recently, EV-miRNAs were reported to be more useful than free miRNAs for the detection of acute kidney injury (AKI) [20]. In addition to AKI, some studies have shown the potential of EV-miRNAs to server as biomarkers in glomerulonephritis, such as for lupus nephritis [21, 22]. Previous EV studies in renal diseases have usually focused on urinary EVs [23, 24], whereas some recent reports have indicated a unique profile of circulating EV-miRNAs for nephrotic syndrome [25–27]. These results suggest that circulating miRNAs could be used as biomarkers for nephrotic syndrome. We also found that EV-miRNA profiles differ between the patients with diabetic nephropathy and those without diabetic nephropathy [28]. However, there is limited data showing the potential role of miRNAs as diagnostic, prognostic, and therapeutic biomarkers for IMN.

In this study, to identify IMN-specific miRNAs at the time of kidney biopsy, we compared the EV-miRNA profiles of patients with IMN and other cohorts, including healthy volunteers (HVs) and patients with INS, using RNA sequencing. Furthermore, we attempted to identify circulating EV-miRNAs predictive of treatment response in patients with IMN by comparing EV-miRNA profiles in patients with and without clinical remission during treatment.

**Materials and methods**

**Participants and data collection**

We included 40 age- and sex-matched patients with IMN and INS and 20 HVs from a prospective glomerular disease cohort. In the present study, INS included focal segmental glomerular sclerosis and minimal change disease, which were defined by the association of the clinical features of nephrotic syndrome with renal biopsy findings of diffuse foot process effacement using electron microscopy [29]. Patients with glomerulonephritis, who were diagnosed between January 2015 and Jun 2020, were enrolled from Soonchunhyang University Hospital and Presbyterian Medical Center. Patients with secondary causes of MN, such as lupus or malignancy, were excluded. This study was approved by the institutional review board of Soonchunhyang University (IRB No. 2016-01-002-007). Written informed consent was obtained from all the participants.

Remissions were defined according to the 2012 Kidney Disease: Improving Global Outcomes guidelines. Among patients with IMN, complete remission was defined as a reduction in proteinuria to 0.3 g/day. Partial remission was defined as a reduction in proteinuria to between 0.3 and 3.5 g/day (with at least 50% reduction versus baseline). Composite remission included either complete remission within 1 year after renal biopsy or partial remission with less than 2.5 g of proteinuria for 2 years following pathologic diagnosis. A refractory response was defined as the absence of composite remission during the follow-up period. Therefore, a total of 19 patients with IMN were divided into two groups: a well- responding (IMN-W) and refractory (IMN-R) group, based on the achievement of composite remission. Anti-PLA2R antibody was measured by ELISA method (EUROIMMUN AG, Lubeck, Germany) using serum sample collected on kidney biopsy.

During the follow-up period, treatment decisions for the enrolled patients were made by the treating nephrologist. The most common reasons for initiating immunosuppressive therapy were patient characteristics (proteinuria, renal function, etc.) that were not properly controlled, and nephrologist clinical judgement.

**Serum EV RNA isolation and assessment**

RNA sequencing was conducted as previously described [30]. Briefly, circulating EVs were isolated from the serum (1000 μL) using the ExoQuick isolation agent (System Bioscience, Palo Alto, CA, USA), according to
After 10 min, the exosomes were fixed with 2.5% glutaraldehyde and stained with 1% uranyl acetate. The samples were diluted ten times with distilled water and the particle size was measured using a transmission electron microscope (TEM). Following sequence alignment, known and novel miRNAs were identified using the miRDeep2 algorithm. Prior to sequence alignment, we retrieved the Homo sapiens reference genome release hg19 from the UCSC Genome Browser. The libraries were gel-purified and validated by assessing their size, purity, and concentration using an Agilent Bioanalyzer (Agilent Technologies, Waldbronn, Germany). Equimolar amounts of libraries were pooled and sequenced on an Illumina HiSeq 2500 instrument (Illumina, San Diego, CA, USA) to generate 51 base reads. Image decomposition and quality value calculations were performed using modules in the Illumina pipeline. All procedures for next-generation sequencing (NGS) analysis were performed at Macrogen (Seoul, Korea).

**Characterization of EVs by cluster of differentiation 63 (CD63) detection**

CD63 levels in circulating EVs were measured using the Exo-enzyme-linked immunosorbent assay (ELISA)-ULTRA CD63 kit (System Biosciences, Palo Alto, CA, USA), according to the manufacturer's protocol.

**Western blot analysis**

Each sample was electrophoresed on SDS-PAGE gels and transferred to nitrocellulose membranes. The membranes were probed with specific antibodies as follows: anti-CD9 (Abcam, Cambridge, MA, USA) and anti-GM-130 (Abcam). The membranes were incubated with horseradish peroxidase-coupled secondary antibody (Sigma). Following washing with TBS-T, the bound antibody was detected by enhanced chemiluminescence (Amersham, Buckinghamshire, UK).

**Transmission electron microscopy (TEM)**

This protocol was performed as described by Thery et al. and Rikkert et al. [31, 32]. A droplet of exosome solution was placed on Para film, and a Formvar-carbon-coated nickel grid (200 meshes, TED PELLA, USA) was floated on the drop to absorb the sample at room temperature. After 10 min, the exosomes were fixed with 2.5% glutaraldehyde and stained with 1% uranyl acetate. The sample was washed with distilled water and dried in the dark. The grid was observed using an electron microscope operating at 75 kV (H-7000B; Hitachi, Tokyo, Japan).

**Exosome physicochemical properties**

A Nano-ZS Zetasizer (Malvern Inc., UK) was used to estimate the particle size. The samples were diluted ten times with distilled water and particle size was measured three times in a set of 50 repetitions using disposable cuvettes (DTS1070; Malvern Inc., Worcestershire, UK) and analyzed using the Zetasizer software (version 7.11).

**Analysis of RNA sequencing data and proportions of miRNAs**

Following sequence alignment, known and novel miRNAs were identified using the miRBase 21. Uniquely clustered reads were sequentially aligned to the reference genome using miRBase 21 and the non-coding RNA database Rfam 9.1 to identify known miRNAs and other types of RNAs, respectively.

**Analysis of miRNA expression levels**

The raw data (reads for each miRNA) were normalized to the relative log expression using DESeq2. For preprocessing, miRNAs absent from more than 50% of all samples were excluded, leaving only mature miRNAs for analysis. We added 1 to the normalized read count of the filtered miRNAs to facilitate log2 transformation and draw a correlation plot. For each miRNA, the base mean and log-fold changes were calculated between the groups. We conducted a statistical hypothesis test to compare
the groups using the negative binomial Wald test in DESeq2. miRNAs differentially expressed between the two groups were defined as having a |fold change| $\geq 2$ and a false discovery rate (FDR)-adjusted p-value of $<0.05$. We also performed hierarchical clustering analysis using complete linkage and Euclidean distance as measures of similarity to display the expression patterns of the differentially expressed miRNAs that satisfied the criteria of a |fold change| $\geq 2$ and an FDR-adjusted p-value of $<0.05$. All data analyses and visualization of the differentially expressed genes were performed using R 3.3.1 (www.r-project.org).

Identification of miRNA target genes and their molecular pathways
We uploaded miRNAs that were differentially expressed in the HVs and patients with IMN-W and IMN-R into commonly used analysis programs, such as DIANA-miRPath and miRSystem, for further analyses. The DIANA-miRPath v.3.0 database used DIANA-microT-CDS and TargetScan 6.2 to analyze miRNA-gene interactions. The database schema incorporated the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, Gene Ontology (GO), and GO slim annotations. Gene and miRNA annotations were derived from the Ensembl and miRBase databases, respectively.

Statistical analysis
Continuous variables with normal distributions are expressed as the mean $\pm$ standard deviation; variables without a normal distribution are expressed as medians with interquartile ranges. The t-test was used to analyze the statistical significance of the differences between continuous variables, and the chi-square test was used for categorical variables to compare the baseline characteristics between HVs and patients with IMN. The IMN group was further divided into two groups, and continuous variables were compared among the three subgroups (HV vs. IMN-W vs. IMN-R) using the Kruskal–Wallis multiple comparison test. Receiver operating characteristics (ROC) analysis was used to calculate the area under the curve (AUC) for each miRNA for the diagnosis and prediction of treatment response in IMN patients. Statistical significance was set at $P < 0.05$. Statistical analysis was performed using SPSS (version 22.0; IBM Corp., Armonk, NY, USA).

Results
Baseline clinical characteristics
The participants included 34 (56%) men, with a mean age of 55 years (range, 25–85 years). The baseline characteristics of the participants are presented in Table 1. HVs had no history of hypertension, diabetes, or medication use.

| Table 1 Comparison of baseline characteristics among three groups |
|---------------------------------------------------------------|
|                  | HV (n = 20) | INS (n = 21) | IMN (n = 19) | P-value |
|------------------|-------------|--------------|--------------|---------|
| Age (years)      | 53 $\pm$ 11 | 56 $\pm$ 16  | 57 $\pm$ 14  | 0.653   |
| Male, n (%)      | 11 (55)     | 12 (57)      | 11 (58)      | 0.488   |
| DM, n (%)        | 0 (0)       | 16 (76)      | 11 (58)      | 0.185   |
| Hypertension, n (%) | 0 (0)      | 11 (52)      | 11 (58)      | 0.488   |
| Hemoglobin (mg/dl) | 13.9 $\pm$ 1.2 | 13.5 $\pm$ 2.3 | 13.0 $\pm$ 1.8 | 0.301   |
| Serum albumin (mg/dl) | 4.6 $\pm$ 0.2  | 2.5 $\pm$ 1.0  | 2.4 $\pm$ 0.5  | $<0.001$ |
| Triglyceride (mg/dl) | 116 $\pm$ 53a | 314 $\pm$ 264b | 300 $\pm$ 199b | $<0.001$ |
| eGFR (ml/min/1.73m²) | 83 $\pm$ 16   | 71 $\pm$ 33   | 79 $\pm$ 22   | 0.268   |
| 24 h-proteinuria (mg/day) | 85 $\pm$ 54a | 9181 $\pm$ 5920b | 7141 $\pm$ 4185b | $<0.001$ |

The same letters (a or b, respectively) indicate non-significant difference between groups based on Kruskal Wallis multiple comparison test.

| Table 2 Comparison of baseline characteristics between two groups |
|---------------------------------------------------------------|
|                  | IMN-W (n = 9) | IMN-R (n = 10) | P-value |
|------------------|--------------|----------------|---------|
| Age (years)      | 56 (37–74)   | 59 (36–84)     | 0.702   |
| Male, n (%)      | 5 (56)       | 6 (60)         | 0.605   |
| DM, n (%)        | 6 (67)       | 5 (50)         | 0.395   |
| Hypertension, n (%) | 7 (78)      | 4 (40)         | 0.115   |
| Hemoglobin (mg/dl) | 12.8 (11.1–15.1) | 12.5 (10.0–18.0) | 0.447   |
| Serum albumin (mg/dl) | 2.2 (1.6–3.6) | 2.3 (1.5–3.0)   | 0.968   |
| Triglyceride (mg/dl) | 242 (146–871) | 209 (123–611)  | 0.447   |
| eGFR (ml/min/1.73m²) | 89 (42–110)  | 75 (48–109)    | 0.549   |
| 24 h-proteinuria, baseline | 6462 (110–17,296) | 8084 (2148–13,044) | 0.356   |
| Anti-PLA2R Ab     | 0.6 (1–214)  | 61.2 (1–566)   | 0.258   |
| Treatment regimen |                 |                |         |
| ACEi or ARB       | 7 (78)       | 10 (100)       | 0.211   |
| Immunosuppressive drugs | 6 (67) | 5 (50)         | 0.395   |
| CsA + Steroid     | 3            | 3              |         |
| CTX + Steroid     | 2            | 1              |         |
| Tac + Steroid     | 1            | 1              |         |

eGFR estimated glomerular filtration rate, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, CsA cyclosporine, CTX cyclophosphamide, Tac tacrolimus.

When we compared the clinical characteristics between the IMN and INS groups, we found no differences in renal function or proteinuria. Similarly, no differences in baseline characteristics were observed between the
Follow-up proteinuria in the IMN-R group was greater than that in the IMN-W group (490 vs. 5458 mg/day, \( p = 0.007 \)) (Table 2). Within the follow-up period, immunosuppressants, including steroids and cyclosporine, were prescribed to six (67%) and five (50%) patients in the IMN-W and in IMN-R groups, respectively. Of the immunosuppressive drugs, combination of cyclosporine and steroid is the most common regimen in both group.

Characterization of circulating EVs and small RNA composition changes

Circulating EVs were isolated and characterized. The median diameter of the EVs measured by dynamic light scattering was \( 179 \pm 73.5 \) nm (Fig. 1A) and \( 161.3 \pm 29.2 \) nm when measured by electron microscopy (Fig. 1B). Western blotting verified that CD9, well-known EV marker protein, was present (Fig. 1C). The absence of GM-130, a Golgi marker, excluded the potential contamination with components with cellular vesicular structures (Fig. 1C) [33]. The levels of CD63, an exosome marker, were higher in the isolated EV samples (Fig. 1DC). EV RNA was isolated and analyzed quality of RNA by bioanalyzer for NGS (Additional file 1: Fig. S1). To examine the EV small RNA composition, we conducted NGS followed by mapping to each small RNA reference database. Using NGS, we identified EV small RNAs, including miRNAs, small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), and transfer RNAs. The proportion of small RNAs that were miRNAs was lower in the IMN-R group than in the HVs and IMN-W group, whereas the proportion that were snoRNAs and snRNAs was higher in the IMN-R group than the HVs and IMN-W groups (Additional file 1: Fig. S2).

---

**Fig. 1** Isolated extracellular vesicles (EVs) from the serum samples of patients. **A** Diagram of the observed peaks of nanoparticles in three patient serum EVs by dynamic light scattering (DLS) using Nano-ZS Zetasizer. **B** Transmission electron microscopy showing membranous vesicles of purified serum EVs. Scale bar, 200 nm. **C** Western blot analysis of EVs using positive marker as CD9 and negative marker as GM-130. **D** Cluster of differentiation 63 (CD63) expression levels in the serum-derived EVs as determined by the enzyme-linked immunosorbent assay (ELISA). Bars represent mean \( \pm \) SD of three EVs from different samples.
Comparison of EV-miRNAs among patients with INS and IMN, and HVs

After RNA sequencing, we identified 33 miRNAs that were upregulated and 11 that were downregulated in patients with INS when compared to HVs (Fig. 2A). We also found three miRNAs that were upregulated and eight that were downregulated in patients with IMN when compared to patients with INS (Fig. 2B). There were 31 miRNAs that were upregulated and 27 that were downregulated in patients with IMN when compared to the HVs (Fig. 2C). Among these miRNAs, we found three miRNAs (miRNA-1229-3p, miRNA-340-3p, and miRNA-99b-5p), whose levels were significantly up- or downregulated in patients with IMN compared to HVs and patients with INS (Fig. 2D). The area under the ROC for each miRNA was shown (Additional file 1: Fig. S5). In addition, the expression levels of two miRNAs (miRNA-192-5p and miRNA-194-5p) in circulating EVs were significantly different in patients with INS compared to those in HVs and IMN groups (Additional file 1: Fig. S4).

Identification and analysis of differentially expressed miRNAs between IMN-W and IMN-R

Furthermore, we found 21 upregulated and 23 downregulated miRNAs in patients with IMN-W when compared to HVs (Additional file 1: Fig. S5). We also found 37 upregulated and 40 downregulated miRNAs in patients with IMN-R when compared to HVs (Additional file 1: Fig. S6). Between the two groups of patients with IMN, there were 24 upregulated and 18 downregulated miRNAs in patients with IMN-R when compared to patients with IMN-W (Fig. 3). Among the differentially expressed miRNAs, we identified 23 that were expressed in patients with IMN-R (Fig. 4). The results of principle component analysis (PCA) using serum-derived EVs from the HV, IMN-W, and IMN-R groups are shown in Fig. 5. We evaluated the predicted biological pathways associated with these miRNAs using the miRSystem. The possible pathways associated with IMN-R are presented in Table 3. miRNAs involved in renal fibrosis are listed in Table 4.
Correlation between EV-miRNAs and clinical parameters
Of the EV-miRNAs that were differentially expressed in patients with IMN-R, the expression levels of miRNA-1285-3p, miRNA-23a-5p, miRNA-483-5p, and miRNA-6126 were found to be directly correlated with proteinuria on kidney biopsy (Table 5). Meanwhile, a negative correlation was observed between renal function and expression of miRNAs, such as miRNA-12136 and miRNA-483-5p. A significant association with the anti-PLA2R antibody was found only for miRNA-23a-5p.

Discussion
In this study, we conducted RNA sequencing to examine the circulating EV-miRNA profiles of patients with IMN and compared them with those of patients with INS and HVs. We identified IMN-specific EV-miRNAs compared to those in HVs or INS subjects. Furthermore, we found that EVs-miRNAs were associated with treatment response in patients with IMN, which will be helpful for clinicians to predict the prognosis of these patients.

Differentially-expressed circulating miRNAs have been found in patients with various glomerular diseases, such as IgA nephropathy and lupus nephritis [34, 35]. Significant differences in the expression profiles of urinary and circulating exosomal miRNAs have also been observed between HVs and patients with IMN [36, 37]. A previous study suggested there is miRNA dysregulation in IMN, in which the differential expression of six miRNAs (upregulation of miR-152 and -15 and downregulation of miR-82, -98, -89, and -84) was observed in patients with IMN when compared to HVs [38]. These miRNAs did not overlap with those identified in the present study. This difference might be due to the source of miRNAs, since the authors of the previous study analyzed miRNAs from peripheral blood lymphocytes. In the present study, we identified three IMN-specific EVs-miRNAs, which might be helpful in discriminating patients with IMN from those with INS or without nephrotic syndrome. Therefore, this study demonstrates the potential of EV-miRNAs as biomarkers for IMN diagnosis.

In addition to these miRNAs, we identified EVs-miRNAs that are helpful in predicting treatment response in patients with IMN. To our knowledge, this is the first study of EV-miRNAs for predicting treatment response in patients with IMN. The prediction of clinical remission in patients with IMN is important for nephrologists because complete or partial remission is associated with good kidney survival [39, 40]. When a refractory case is anticipated with conventional therapy, the clinician may be able to come up with alternative
treatment options to avoid the adverse effects of immunosuppressive drugs. In our study, we identified 23 miRNAs that were differentially expressed in patients with IMN-R which were distinct from those in patients with IMN-W. Interestingly, such pathways seem to be associated with cancers. Although the causality link

| Mature_ID          | FC (log2 scale) | p-value | FC (log2 scale) | p-value | FC (log2 scale) | p-value |
|--------------------|-----------------|---------|-----------------|---------|-----------------|---------|
| hsa-let-7f-1-3p    | -1.03           | 0.8626  | -2.39           | 0.0003  | 2.35            | 0.0081  |
| hsa-miR-106b-3p    | -1.17           | 0.6032  | -3.77           | 0.0001  | 3.23            | 0.0008  |
| hsa-miR-12136      | -1.65           | 0.1616  | 2.66            | 0.0002  | -4.35           | 0.0006  |
| hsa-miR-1273c      | 1.14            | 0.3462  | 4.63            | 0.0000  | -4.15           | 0.0010  |
| hsa-miR-1285-3p    | 1.51            | 0.1793  | 4.64            | 0.0000  | -3.10           | 0.0028  |
| hsa-miR-146-3p     | -1.24           | 0.9038  | 7.27            | 0.0001  | -9.24           | 0.0012  |
| hsa-miR-148b-3p    | 1.07            | 1.0000  | -7.70           | 0.0007  | 8.45            | 0.0007  |
| hsa-miR-150b-3p    | 1.29            | 0.3150  | -2.08           | 0.0025  | 2.72            | 0.0059  |
| hsa-miR-186a-5p    | -1.42           | 0.2995  | -6.09           | 0.0001  | 4.20            | 0.0094  |
| hsa-miR-224-5p     | -1.93           | 0.0769  | -15.56          | 0.0000  | 8.43            | 0.0010  |
| hsa-miR-23a-5p     | 1.14            | 0.5379  | 2.59            | 0.0004  | -2.26           | 0.0027  |
| hsa-miR-30b-5p     | -1.27           | 0.4306  | -5.44           | 0.0001  | 4.32            | 0.0017  |
| hsa-miR-331-3p     | -1.56           | 0.3008  | -4.21           | 0.0000  | 2.80            | 0.0021  |
| hsa-miR-425-5p     | -1.03           | 0.8273  | -2.33           | 0.0000  | 2.23            | 0.0028  |
| hsa-miR-483-5p     | 1.50            | 0.1642  | 4.67            | 0.0000  | -3.07           | 0.0095  |
| hsa-miR-548a-5p    | -1.72           | 0.0821  | 2.38            | 0.0000  | -4.12           | 0.0007  |
| hsa-miR-548b-3p    | -1.72           | 0.0822  | 2.38            | 0.0001  | -4.12           | 0.0007  |
| hsa-miR-568b       | 1.62            | 0.0281  | 3.73            | 0.0000  | -2.28           | 0.0074  |
| hsa-miR-6126       | -1.38           | 0.0602  | -4.25           | 0.0000  | 3.29            | 0.0181  |
| hsa-miR-625-3p     | -1.16           | 1.0000  | 2.49            | 0.0000  | -2.95           | 0.0090  |
| hsa-miR-6873-3p    | -1.20           | 1.0000  | 3.10            | 0.0071  | -3.76           | 0.0253  |
| hsa-miR-8485       | 1.25            | 0.4058  | 3.21            | 0.0000  | -2.56           | 0.0104  |

Fig. 4 Identification of idiopathic membranous nephropathy without clinical remission (IMN-R)-specific EVs-miRNAs. **A** Venn diagram of overlapping miRNAs among the three datasets shows 23 miRNAs expressed in patients with IMN-R. **B** Fold change (FC) and p-values of 23 miRNAs, whose expression levels were up- or down-regulated in patients with IMN-R compared to HVs and IMN-W.

Fig. 5 Principle component analysis (PCA) of serum-derived EVs. **A** Results of PCA using serum-derived EVs from HVs, IMN, and INS. **B** Results of PCA using serum-derived EVs from HVs, IMN-W, and IMN-R.
### Table 3 Top list of possible canonical pathways associated with 23 miRNAs which differentially expressed in patients with IMN-R

| KEGG Pathway                        | Total genes | miRNAs | p-value    |
|-------------------------------------|-------------|--------|------------|
| Proteoglycans in cancer             | 95          | 17     | 1.25E-07   |
| TGF-beta signaling pathway          | 46          | 15     | 2.26E-07   |
| Long-term depression                | 35          | 15     | 2.69E-07   |
| Hippo signaling pathway             | 73          | 16     | 2.26E-07   |
| Prion diseases                      | 12          | 11     | 7.45E-07   |
| Transcriptional misregulation in cancer | 84    | 18     | 1.02E-06   |
| Gloma                               | 38          | 15     | 2.42E-06   |
| Renal cell carcinoma                | 43          | 15     | 4.93E-06   |
| Chronic myeloid leukemia            | 45          | 15     | 4.99E-06   |
| FoxO signaling pathway              | 73          | 16     | 6.65E-06   |
| Axon guidance                       | 68          | 15     | 1.45E-05   |
| Acute myeloid leukemia              | 36          | 14     | 1.66E-05   |
| Pathways in cancer                  | 178         | 17     | 1.67E-05   |
| Rap1 signaling pathway              | 105         | 18     | 2.48E-05   |
| Viral carcinogenesis                | 83          | 18     | 2.60E-05   |
| Adherens junction                   | 44          | 16     | 4.85E-05   |
| Colorectal cancer                   | 40          | 15     | 9.85E-05   |
| Signaling pathways regulating pluripotency of stem cells | 69 | 17 | 0.000102 |
| Focal adhesion                      | 102         | 15     | 0.000137   |
| Non-small lung cancer               | 32          | 15     | 0.000151   |

### Table 4 Relationship between renal fibrosis pathway and miRNAs associated with IMN-R

| miRNAs                  | TGF-beta | Hippo | FOXO | Rap1 | Proteoglycan |
|-------------------------|----------|-------|------|------|--------------|
| hsa-let-7f-1-3p         | ●        | ●     | ●    | ●    | ●            |
| hsa-miR-1273c           | ●        | ●     | ●    | ●    | ●            |
| hsa-miR-1285-3p         | ●        | ●     | ●    | ●    | ●            |
| hsa-miR-148b-3p         | ●        | ●     | ●    | ●    | ●            |
| hsa-miR-15b-3p          | ●        | ●     | ●    | ●    | ●            |
| hsa-miR-181a-5p         | ●        | ●     | ●    | ●    | ●            |
| hsa-miR-224-5p          | ●        | ●     | ●    | ●    | ●            |
| hsa-miR-23a-5p          | ●        | ●     | ●    | ●    | ●            |
| hsa-miR-30b-5p          | ●        | ●     | ●    | ●    | ●            |
| hsa-miR-425-5p          | ●        | ●     | ●    | ●    | ●            |
| hsa-miR-483-5p          | ●        | ●     | ●    | ●    | ●            |
| hsa-miR-548aa           | ●        | ●     | ●    | ●    | ●            |
| hsa-miR-548t-3p         | ●        | ●     | ●    | ●    | ●            |
| hsa-miR-5684            | ●        | ●     | ●    | ●    | ●            |
| hsa-miR-6126            | ●        | ●     | ●    | ●    | ●            |
| hsa-miR-625-3p          | ●        | ●     | ●    | ●    | ●            |
| hsa-miR-642a-3p         | ●        | ●     | ●    | ●    | ●            |
| hsa-miR-6873-3p         | ●        | ●     | ●    | ●    | ●            |
| hsa-miR-8485            | ●        | ●     | ●    | ●    | ●            |

● Presence  
● Absence
such as let-7f and miR-23a, were also found to be associated with the FoxO and Hippo pathways, similar to the TGF-β pathway. Previous studies have also reported such a relationship in other diseases [55, 56]. Intriguingly, PCA of serum-derived EVs from HVs and the IMN, and INS groups revealed a relatively poor demarcation. However, PCA revealed some overlap between the serum-derived EVs from HVs and those from patients with IMN-W, with a fully distinct miRNA profile for serum-derived EVs from patients with IMN-R. Although these results might imply that fibrotic changes in IMN-R are important factors affecting treatment response, further studies are needed to investigate the pathological mechanism for predicting the clinical responses of patients with IMN. Our study had some limitations. First, the number of enrolled participants was relatively small; therefore, larger prospective randomized controlled trials are needed to confirm our results. Next, EV RNA was isolated using commercial kits; however, isolation using other methods may yield different results. To date, there is no gold standard method for EV isolation. Finally, we could not validate our findings in different cohorts, and this can be taken up in future studies.

Conclusions
Our study revealed circulating EV-miRNAs that can discriminate patients with IMN from HVs and those with INS. Furthermore, we identified circulating EV-miRNAs that are associated with clinical remission in patients with IMN, which may be used as surrogate markers for predicting clinical remission in these patients during treatment. However, further studies are needed to confirm the utility of EV-miRNAs in diagnosing IMN and predicting clinical remission in patients with IMN.

Abbreviations
IMN: Idiopathic membranous nephropathy; IMN-R IMN with refractory response; IMN-W IMN with well response; INS: Idiopathic nephrotic syndrome; PLA2R: Anti-phospholipase A2 receptor; EVs: Extracellular vesicles; miRNA: MicroRNA; AKI: Acute kidney injury; HV: Healthy volunteer; PCR: Polymerase chain reaction; qPCR: Quantitative PCR; NGS: Next-generation sequencing; FDR: False discovery rate; KEGG: Kyoto Encyclopedia of Genes; GO: Gene Ontology; snRNA: Small nuclear RNA; snoRNA: Small nucleolar RNA; TGF-β: Transforming growth factor-β; FoxO: Forkhead homobox type O.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12967-022-03430-7.

**Table 5** Correlation of differentially expressed miRNAs in IMN-W and –R with clinical parameters

|                | GFR r | GFR p | 24-Proteinuria r | 24-Proteinuria p | Anti-PLA2R Ab r | Anti-PLA2R Ab p |
|----------------|-------|-------|------------------|------------------|-----------------|-----------------|
| **IMN-W miRNAs** |       |       |                  |                  |                 |                 |
| hsa-miR-107    | 0.017 | 0.919 |                  |                  | −0.230          | 0.374           |
| hsa-miR-32-5p  | 0.188 | 0.288 |                  |                  | 0.205           | 0.244           |
| hsa-miR-424-5p | 0.077 | 0.651 |                  | 0.187            | 0.268           | 0.275           |
| hsa-miR-451a   | 0.217 | 0.185 |                  | 0.070            | 0.674           | −0.316          |
| **IMN-R miRNAs** |       |       |                  |                  |                 |                 |
| hsa-let-7F-1-3p | 0.075 | 0.665 | −0.370           | 0.027            |                 |                 |
| hsa-miR-106-3p | −0.097 | 0.592 | −0.263           | 0.139            | 0.241           | 0.427           |
| hsa-miR-12136  | −0.460 | 0.003 | 0.043            | 0.793            | 0.233           | 0.353           |
| hsa-miR-1285-3p| −0.251 | 0.129 |                  | 0.447            | 0.005           |                 |
| hsa-miR-15b-3p | 0.098  | 0.558 | −0.252           | 0.127            | −0.267          | 0.300           |
| hsa-miR-23a-5p | −0.185 | 0.272 |                  | 0.375            | 0.022           | 0.616           |
| hsa-miR-425-5p | 0.163  | 0.321 | −0.366           | 0.022            | −0.006          | 0.981           |
| hsa-miR-483-5p | −0.366 | 0.022 | 0.372            | 0.020            | 0.274           | 0.270           |
| hsa-miR-6126   | −0.228 | 0.163 |                  | 0.504            | 0.001           | 0.157           |
| hsa-miR-625-3p | 0.005  | 0.979 | −0.302           | 0.093            | −0.479          | 0.098           |
| hsa-miR-8485   | −0.291 | 0.073 | 0.289            | 0.074            | 0.390           | 0.110           |

Statistically significant data are shown in bold
Acknowledgements
None.

Author contributions
IOS, YUB, KOD and SHK conceived and designed the study. IOS, YUB, KOD and SHK performed statistical analysis. IOS, KOD and SHK wrote the manuscript. All authors read and approved the final version of the manuscript.

Funding
This research was supported by the Engineering Research Center Program (2018R1A5A1025511) and the Ministry of Education (NRF-2020R1I1A3A04037367) through the National Research Foundation of Korea (NRF) and the Soonchunhyang University Research Fund. The biospecimens and data used for this study were provided by the Biobank of Soonchunhyang University Seoul Hospital and the Biobank of Seoul National University Hospital, a member of the Korea Biobank Network (KBN4_A03).

Availability of data and materials
As the study involved human participants, the data cannot be made freely available in the manuscript nor a public repository because of ethical restrictions. However, the data are available from Soonchunhyang University Hospital for researchers who meet the criteria for access to confidential data. Interested researchers can send data access requests to the corresponding author (KY, Doh, SH. Kwon).

Declarations
Ethics approval and consent to participate
This study was conducted with participants who voluntarily provided informed consent and carried out in accordance with the Declaration of Helsinki, and the study protocol was approved by the institutional review board of Soonchunhyang University Seoul Hospital (2016–01–002–007).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Division of Nephrology, Department of Internal Medicine, Presbyterian Medical Center, Jeonju, Republic of Korea. 2 Department of Internal Medicine, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Republic of Korea. 3 Division of Nephrology, Soonchunhyang University Seoul Hospital, 59 Daesagwan-ro, Youngsan-gu, Seoul 04401, Republic of Korea. 4 Department of Physiology, College of Medicine, Yeungnam University, Daegu 42415, Republic of Korea.

References
1. Kodner C. Diagnosis and management of nephrotic syndrome in adults. Am Fam Physician. 2016;93(6):479–85.
2. McGroghan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414–30.
3. Dawin JC. The glomerular permeability factors in idiopathic nephrotic syndrome. Pediatr Nephrol. 2016;31(2):207–15.
4. Candelier JJ, Lorenzo HK. Idiopathic nephrotic syndrome and serum permeability factors: a molecular jigsaw puzzle. Cell Tissue Res. 2020;379(2):231–43.
5. McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010;5(11):2115–21.
6. De Vriese AS, Glasscock RJ, Nath KA, Sethi S, Fervenza FC. A Proposal for a serology‑based approach to membranous nephropathy. J Am Soc Nephrol. 2017;28(2):421–30.
7. Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, et al. Rituximab‑induced depletion of anti‑PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. 2011;22(8):1543–50.
8. Hoxha E, Thiele I, Zahner G, Panzer U, Harenzda S, Stahl RA. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol. 2014;25(6):1357–66.
9. Wang J, Xie Q, Sun Z, Xu N, Li Y, Wang L, et al. Response to immunosuppressive therapy in PLA2R‑associated and non‑PLA2R‑associated idiopathic membranous nephropathy: a retrospective, multicenter cohort study. BMC Nephrol. 2017;18(1):277.
10. Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med. 2011;364(7):689–90.
11. Hoxha E, Kreisler U, Stege G, Zahner G, Thiele I, Panzer U, et al. Enhanced expression of the M‑type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int. 2012;82(7):797–804.
12. Hofstra JM, Beck LH Jr, Beck DM, Wetzelis JF, Salant DJ. Anti‑phospholipase A2(2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1286–91.
13. Hoxha E, Harenzda S, Pinnenschmidt HO, Tomas NM, Helmchen U, Panzer U, et al. Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody‑negative patients with membranous nephropathy. Nephrol Dial Transplant. 2015;30(11):1862–9.
14. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummings TD, et al. M‑type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(11):11–21.
15. Kanigichera D, Gummadova J, McKenzie EA, Roberts SA, Harris S, Nakimar M, et al. Anti‑PLA2R antibodies measured by ELISA predict long‑term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. 2013;83(3):940–8.
16. Hofstra JM, Wetzelis JF. Phospholipase A2 receptor antibodies in membranous nephropathy: unresolved issues. J Am Soc Nephrol. 2014;25(6):1137–9.
17. Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L. Exosomes/ microvesicles as a mechanism of cell‑to‑cell communication. Kidney Int. 2010;78(9):838–48.
18. Hessvik NP, Lorentz A. Current knowledge on exosome biogenesis and release. Cell Mol Life Sci. 2018;75(2):193–208.
19. Sharkey JW, Antoine DJ, Park BK. Validation of the isolation and quantification of kidney enriched miRNAs for use as biomarkers. Biomarkers. 2012;17(3):231–9.
20. Yun CY, Lim JH, Oh JH, Cho AY, Lee KY, Sun IO. Urinary exosomal microRNA‑21 as a marker for scrub typhus‑associated acute kidney injury. Genet Test Mol Biomarkers. 2021;25(2):140–4.
21. Perez-Hernandez J, Forner MJ, Pinto C, Chaves FJ, Cortes R, Redon J. Increased urinary exosomal microRNAs in patients with systemic lupus erythematosus. PLoS ONE. 2015;10(9):e0138618.
22. Guan J, Wang G, Tam LS, Kwan BC, Li EK, Chow KM, et al. Urinary sediment ICAM-1 level in lupus nephritis. Lupus. 2012;21(11):1190–5.
23. Sun IO, Kwon SH. Extracellular vesicles: a novel window into kidney function and disease. Curr Opin Nephrol Hypertens. 2020;29(6):613–9.
24. Choi D, Kim S, Woo J, Lee H, Kim H, Jeon JS, et al. Weight change alters the small RNA profile of urinary extracellular vesicles in obesity. Obes Facts. 2022. https://doi.org/10.1159/000521730.
25. Ramezani A, Devaney JM, Cohen S, Wing MR, Scott R, Knoblach S, et al. Circulating and urinary microRNA profile in focal segmental glomerulosclerosis: a pilot study. Eur J Clin Invest. 2015;45(4):394–404.
26. Xiao B, Wang LN, Li W, Gong L, Yu T, Zuo QF, et al. Plasma microRNA panel is a novel biomarker for focal segmental glomerulosclerosis and associated with podocyte apoptosis. Cell Death Dis. 2018;9(5):533.
27. Zhang C, Zhang W, Chen HM, Liu C, Wu J, Shi S, et al. Plasma microRNA-186 and proteinuria in focal segmental glomerulosclerosis. Am J Kidney Dis. 2015;65(2):222–32.
28. Kim H, Baie YU, Jeon JS, Noh H, Park HK, Byun DW, et al. The circulating exosomal microRNAs related to albuminuria in patients with diabetic nephropathy. J Transl Med. 2019;17(1):236.
29. White RH, Glasgow EF, Mills RJ. Clinopathological study of nephrotic syndrome in childhood. Lancet. 1970;1(7656):1533–9.
30. Baie YU, Kim Y, Lee H, Kim H, Jeon JS, Noh H, et al. Bariatric surgery alters microRNA content of circulating exosomes in patients with obesity. Obesity (Silver Spring). 2019;27(2):264–71.
31. Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006. https://doi.org/10.1002/0471143030.cb0322s30.
32. Rikkert LG, Nieuwland R, Terstappen L, Coumans FAW. Quality of extracellular RNA isolation and disease. Curr Opin Nephrol Hypertens. 2020;29(6):613–9.
33. Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for study of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1555419.
34. Wang Z, Liao Y, Wang L, Lin Y, Ye Z, Zeng X, et al. Small RNA deep sequencing reveals novel miRNAs in peripheral blood mononuclear cells from patients with IgA nephropathy. Mol Med Rep. 2020;22(4):3378–86.
35. Li W, Liu S, Chen Y, Weng R, Zhang K, He X, et al. Circulating exosomal microRNAs as biomarkers of systemic lupus erythematosus. Clinics (Sao Paulo). 2020;75: e1528.
36. Zhang J, Zhu Y, Cai R, Jin J, He Q. Differential expression of urinary exosomal small RNAs in idiopathic membranous nephropathy. Biomed Res Int. 2020;2020:3170927.
37. Ma H, Xu Y, Zhang R, Guo B, Zhang S, Zhang X. Differential expression study of circular RNAs in exosomes from serum and urine in patients with idiopathic nephropathy. Arch Med Sci. 2019;15(3):738–53.
38. Chen W, Lin X, Huang J, Tan K, Chen Y, Peng W, et al. Integrated profiling of microRNA expression in membranous nephropathy using high-throughput sequencing technology. Int J Mol Med. 2014;33(1):25–34.
39. Thompson A, Cattran DC, Blank M, Nachman PH. Complete and partial remission as surrogate end points in membranous nephropathy. J Am Soc Nephrol. 2015;26(12):2980–93.
40. Cattran DC, Brenchley PE. Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int. 2017;91(3):566–74.
41. von Haehausen F, Reinhard L, Pirninschmidt HO, Rink M, Soave A, Hoeha E, et al. Antigen-specific IgG subclasses in primary and malignancy-associated membranous nephropathy. Front Immunol. 2018;9:3035.
42. Sutariya B, Jhonsa D, Saraf MN. TGF-beta: the connecting link between nephropathy and fibrosis. Immunopharmacol Immunotoxicol. 2016;38(1):39–49.
43. Tsakas S, Goumenos DS. Accurate measurement and clinical significance of urinary transforming growth factor-beta 1. J Am J Nephrol. 2006;26(2):186–93.
44. Camilla R, Brachem S, Pichette V, Cartier P, Lafosse-Renald A, MacRae T, et al. Urinary monocyte chemotactic protein 1: marker of renal function decline in diabetic and nondiabetic proteinuric renal disease. J Nephrol. 2011;24(1):60–7.
45. De Muro P, Faedd A, Fescu P, Masala A, Cigni A, Concias G, et al. Urinary transforming growth factor-beta 1 in various types of nephropathy. Pharmacol Res. 2004;49(3):293–8.
46. Honkanen E, Teppo AM, Tornroth T, Groop PH, Gronhagen-Riska C. Urinary transforming growth factor-beta 1 in membranous glomerulonephritis. Nephrol Dial Transplant. 1997;12(12):2562–8.
47. Waserstein AG. Membranous glomerulonephritis. J Am Soc Nephrol. 1997;8(4):664–74.
48. Zuo K, Wu Y, Li SI, Xu F, Zeng CH, Liu ZH. Long-term outcome and prognostic factors of idiopathic membranous nephropathy in the Chinese population. Clin Nephrol. 2013;79(6):445–53.
49. Kang K, Liao X, Li Q, Chen J, Niu Y, Zeng Y, et al. A novel toxicity-responsive microRNA miR-23a-5p modulates renal cell survival under osmotic stress through targeting heat shock protein 70 HSPA1B. Am J Physiol Cell Physiol. 2021;320(2):C225–39.
50. Zhang H, Yan Y, Hu Q, Zhang X. LncRNA MALAT1/microRNA let-7f/KLF5 axis regulates podocyte injury in diabetic nephropathy. Life Sci. 2021;266:118794.
51. Costanza B, Umelo IA, Bellier J, Castronovo V, Turriott A. Stromal modulators of TGF-beta in cancer. J Clin Med. 2017;6(7).
52. Attisano L, Wrana JL. Signal integration in TGF-beta, WNT, and Hippo pathways. F1000Prime Rep. 2013;5:17.
53. Varelas X, Miller BW, Sopko R, Song S, Gregoireff A, Fellouze FA, et al. The Hippo pathway regulates Wnt/beta-catenin signaling. Dev Cell. 2010;18(4):579–91.
54. Ding H, Bai F, Gao H, Xu J, Fang L, Wu J, et al. PDE/cAMP/Epcap/C/EBP-beta signaling cascade regulates mitochondria biogenesis of tubular epithelial cells in renal fibrosis. Antioxid Redox Signal. 2018;29(7):637–52.
55. Wang H, Chen M, Xu P, Pan Y, Zhang Y, Huang H, et al. Abnormal regulation of microRNAs and related genes in pediatric beta-thalassemia. J Clin Lab Anal. 2021;35(9): e23945.
56. Zhuo Z, Wang C, Yu H. Plasma microRNAs can be a potential diagnostic biomarker for endometriosis. Ginekol Pol. 2021. https://doi.org/10.5103/GPA2021.0127.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year